Loading companies…
AnaCardio
Sweden · Biotech · Healthtech
AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.
A drug program aimed at cardiac function
AnaCardio’s lead program AC01 is an oral small-molecule ghrelin mimetic being developed as a contractile agent for heart failure. The approach is intended to improve the heart’s ability to contract, addressing cardiac function rather than only the symptoms that accompany the disease.
Clinical development
The company is advancing AC01 through clinical development and reported its earlier entry into patient studies in heart failure. Its current work is drug research and development; any future trial phase or commercial availability remains dependent on clinical results and regulatory review.
- Lead program
- AC01
- Indication
- Heart failure
- Company stage
- Clinical-stage biopharmaceutical
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | €62.5M | Ljungström family office — LeadNovo Holdings — LeadFlerie — ParticipantHelsinn — ParticipantIndustrifonden — ParticipantInnovestor Life Science — ParticipantLLD Nybohov Invest AB — ParticipantPureos Bioventures — ParticipantSound Bioventures — Participant |
Investors
Ljungström family officeLed Series BNovo HoldingsLed Series BFlerieJoined Series BHelsinnJoined Series BIndustrifondenJoined Series BInnovestor Life ScienceJoined Series BLLD Nybohov Invest ABJoined Series BPureos BioventuresJoined Series BSound BioventuresJoined Series BCoverage
Sep 30, 2026AnaCardio · Series BSimilar companies
GMGeneral MedicineAn online healthcare store where people compare care options and upfront prices, book visits and order medications or lab tests.$120M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
Blue Health IntelligenceBlue Health Intelligence combines a one-hour health assessment with doctor-led interpretation and a digital plan for preventive care.€3.4M · €3.4 million growth capital